It seems the clinical collaboration started in 2015, nothing was mentioned about the financial aspect of it until 2018, two drug one anti PD-1 another growth enzyme inhibitor both were already approved for treatment of various cancers. Based on the financial update in 2018 Merck must have had high hopes with upfront payment etc. "Financial Considerations
...more